2017
DOI: 10.1038/srep41271
|View full text |Cite
|
Sign up to set email alerts
|

Tryptophan-2,3-Dioxygenase (TDO) deficiency is associated with subclinical neuroprotection in a mouse model of multiple sclerosis

Abstract: The catabolism of tryptophan to immunosuppressive and neuroactive kynurenines is a key metabolic pathway regulating immune responses and neurotoxicity. The rate-limiting step is controlled by indoleamine-2,3-dioxygenase (IDO) and tryptophan-2,3-dioxygenase (TDO). IDO is expressed in antigen presenting cells during immune reactions, hepatic TDO regulates blood homeostasis of tryptophan and neuronal TDO influences neurogenesis. While the role of IDO has been described in multiple immunological settings, little i… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
41
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
10

Relationship

1
9

Authors

Journals

citations
Cited by 48 publications
(44 citation statements)
references
References 58 publications
1
41
0
Order By: Relevance
“…Kynurenine aminotransferase (KAT1) converts kynurenine into kynurenic acid, an inhibitor of NMDA glutamate receptors [ 95 , 96 , 97 , 98 ] and α7-nicotinic (neuronal) acetylcholine receptors [ 96 , 97 , 99 ]. I3AA inhibits human KAT1, thereby blocking formation of kynurenic acid [ 100 ].…”
Section: Resultsmentioning
confidence: 99%
“…Kynurenine aminotransferase (KAT1) converts kynurenine into kynurenic acid, an inhibitor of NMDA glutamate receptors [ 95 , 96 , 97 , 98 ] and α7-nicotinic (neuronal) acetylcholine receptors [ 96 , 97 , 99 ]. I3AA inhibits human KAT1, thereby blocking formation of kynurenic acid [ 100 ].…”
Section: Resultsmentioning
confidence: 99%
“…patients and healthy subjects (19). Interestingly, whereas several pieces of evidence would indicate IDO1 as a protective player in RRMS (55,56), lack of TDO expression will protect mice with EAE from neuronal loss in the spinal cord (57). Because of the protective effects of NAS in WT mice with EAE, we investigated whether the Trp metabolite could modulate IDO1 activity in PBMCs from RRMS patients.…”
Section: Nas Confers Immunosuppressive Effects On Dcs Via Increased Cmentioning
confidence: 99%
“…Murine models of the disease have also implicated Trp metabolism. Tdo2 deficiency (the gene encoding hepatic TDO) is protective in EAE (128). However, DC-targeted type 1 IFN treatment decreased EAE severity by upregulating Ido1 expression and inducing a tolerogenic DC phenotype (129).…”
Section: Tryptophan Metabolites In Autoimmunitymentioning
confidence: 99%